89bio kicks off Phase III trial for pegozafermin in MASH

89bio has initiated its Phase III trial ENLIGHTEN-Fibrosis evaluating pegozafermin in patients with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) patients with advanced forms of fibrosis.

The trial is one of two studies in the US biopharma’s Phase III ENLIGHTEN programme testing the efficacy and safety of the recombinant protein.